Selective β3-adrenoceptor agonists for the treatment of overactive bladder

Journal of Urology

Volumn 190, Issue 4, 2013, Pages 1173-1180

  Andersson, Karl Erik ^a   Martin, Nancy ^b   Nitti, Victor ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

mirabegron; muscle smooth; receptors adrenergic; solabegron; urinary bladder overactive

Indexed keywords

BUTOXAMINE; METOPROLOL; MIRABEGRON; PLACEBO; PRACTOLOL; PROPRANOLOL; SOLABEGRON; TERBUTALINE; TOLTERODINE;

ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER CONTRACTION; BLADDER FILLING; BLOOD PRESSURE; CHOLINERGIC NERVE; CONSTIPATION; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG EXCRETION; DRUG TOLERABILITY; DYSPEPSIA; EFFERENT NERVE; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; LEYDIG CELL; MICTURITION REFLEX; MUSCLE EXCITATION; NAUSEA; NEUROTRANSMITTER RELEASE; OVERACTIVE BLADDER; PHARMACOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NERVE; SIDE EFFECT; TREATMENT DURATION; URINE INCONTINENCE; URINE VOLUME; URODYNAMICS; XEROSTOMIA;

EID: 84883771990     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.02.104     Document Type: Review

References (50)

1. R.P. Ahlquist A study of the adrenotropic receptors Am J Physiol 153 1948 586
2. A.M. Lands, A. Arnold, and J.P. McAuliff Differentiation of receptor systems activated by sympathomimetic amines Nature 214 1967 597
3. L.J. Emorine, S. Marullo, and M.M. Briend-Sutren Molecular characterization of the human beta 3-adrenergic receptor Science 245 1989 1118
4. M.G. Ursino, V. Vasina, and E. Raschi The beta3-adrenoceptor as a therapeutic target: current perspectives Pharmacol Res 59 2009 221
5. M.C. Michel, P. Ochodnicky, and R.J. Summers Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges Naunyn Schmiedeb Arch Pharmacol 382 2010 103
6. K.E. Andersson Pharmacology of lower urinary tract smooth muscles and penile erectile tissues Pharmacol Rev 45 1993 253
7. A. Nergårdh, L.O. Boréus, and A.S. Naglo Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat Acta Pharmacol Toxicol (Copenh) 40 1977 14
8. J.J. Larsen Alpha and beta-Adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man Br J Pharmacol 65 1979 215
9. P. Lindholm, and G. Lose Terbutaline (Bricanyl) in the treatment of female urge incontinence Urol Int 41 1986 158
10. K.E. Andersson, C.R. Chapple, and L. Cardozo Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence Curr Opin Urol 19 2009 380
11. Michel MC and Vrydag W: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, suppl., 2006; 147: S88.
12. A. Otsuka, H. Shinbo, and R. Matsumoto Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium Naunyn Schmiedebergs Arch Pharmacol 377 2008 473
13. M. Nomiya, and O. Yamaguchi A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders J Urol 170 2003 649
14. E.P. Frazier, S.L. Peters, and A.S. Braverman Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors Naunyn Schmiedebergs Arch Pharmacol 377 2008 449
15. M.C. Michel, P. Ochodnicky, and Y. Homma β-adrenoceptor agonist effects in experimental models of bladder dysfunction Pharmacol Ther 131 2011 40
16. A. Roosen, C.R. Chapple, and R.R. Dmochowski A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature Eur Urol 56 2009 810
17. A. Kanai, and K.E. Andersson Bladder afferent signaling: recent findings J Urol 183 2010 1288
18. J.I. Gillespie The autonomous bladder: a view of the origin of bladder overactivity and sensory urge BJU Int 93 2004 478
19. A. Iggo Tension receptors in the stomach and the urinary bladder J Physiol 128 1955 593
20. N. Aizawa, Y. Igawa, and O. Nishizawa Effects of CL316,243, a beta 3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat Neurourol Urodyn 29 2010 771
21. N. Aizawa, Y. Homma, and Y. Igawa Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin Eur Urol 62 2012 1165
22. S.M. Biers, J.M. Reynard, and A.F. Brading The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder BJU Int 98 2006 1310
23. Andersson KE: Bladder activation: afferent mechanisms. Urology, suppl., 2002; 59: 43.
24. L.A. Birder, and W.C. de Groat Mechanisms of disease: involvement of the urothelium in bladder dysfunction Nat Clin Pract Urol 4 2007 46
25. S. Murakami, C.R. Chapple, and H. Akino The role of the urothelium in mediating bladder responses to isoprenaline BJU Int 99 2007 669
26. B.J. Limberg, K.E. Andersson, and F. Aura Kullmann β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder Cell Tissue Res 342 2010 295
27. E.P. Frazier, M.J. Mathy, and S.L. Peters Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther 313 2005 260
28. G.V. Petkov Role of potassium ion channels in detrusor smooth muscle function and dysfunction Nat Rev Urol 9 2011 30
29. A. Hicks, G.P. McCafferty, and E. Riedel GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog J Pharmacol Exp Ther 323 2007 202
30. 3-adrenoceptors in the human heart? Br J Pharmacol 162 2011 817
31. C. Gauthier, B. Rozec, and B. Manoury Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies Curr Heart Fail Rep 8 2011 184
32. Astellas Pharma US: Highlights of Prescribing Information. Available at http://www.us.astellas.com/docs/myrbetriq-full-pi.pdf. Accessed February 17, 2013.
33. 3-adrenoceptor activation increases force and Ca(2+) current at physiological temperature Br J Pharmacol 162 2011 823
34. C. Dessy, and J.L. Balligand Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives Adv Pharmacol 59 2010 135
35. T. Takasu, M. Ukai, and S. Sato Effect of (R)-2-(2-aminothiazol-4-yl)- 4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function J Pharmacol Exp Ther 321 2007 642
36. Y. Igawa, and M.C. Michel Pharmacological profile of β(3)- adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome Naunyn Schmiedebergs Arch Pharmacol 386 2013 177
37. S. Kanie, A. Otsuka, and S. Yoshikawa Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips Urology 79 2012 744
38. S. Takusagawa, J.J. van Lier, and K. Suzuki Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers Drug Metab Dispos 40 2012 815
39. S. Takusagawa, K. Yajima, and A. Miyashita Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist Xenobiotica 42 2012 957
40. S. Takusagawa, A. Miyashita, and T. Iwatsubo In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist Xenobiotica 42 2012 1187
41. 3-adrenoceptor agonist for treatment of overactive bladder Int J Clin Pharmacol Ther 50 2012 838
42. W. Krauwinkel, J. van Dijk, and M. Schaddelee Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women Clin Ther 34 2012 2144
43. M. Malik, E.M. van Gelderen, and J.H. Lee Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study Clin Pharmacol Ther 92 2012 696
44. C.R. Chapple, O. Yamaguchi, and A. Ridder Clinical proof of concept study (BLOSSOM) shows novel Beta3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder Eur Urol Suppl 7 2008 239
45. C. Chapple, J.J. Wyndaele, and P. Van Kerrebroeck Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3-adrenoceptor agonist, in patients with overactive bladder (OAB) Eur Urol Suppl 9 2010 249
46. V.W. Nitti, S. Auerbach, and N. Martin Results of a randomized phase III trial of mirabegron in patients with overactive bladder J Urol 189 2013 1388
47. V. Khullar, G. Amarenco, and J.C. Angulo Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial Eur Urol 63 2013 283
48. van Kerrebroeck P, Barkin J, Castro-Diaz D, et al. Randomised, double-blind, placebo-controlled phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). Presented at annual meeting of International Continence Society, Beijing, People's Republic of China, October 19, 2012, poster 359. Available at http://www.icsoffice.org/Abstracts/Publish/134/000359.pdf. Accessed February 17, 2013.
49. C.R. Chapple, S.A. Kaplan, and D. Mitcheson Randomized Double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder Eur Urol 63 2013 296
50. E.H. Ohlstein, A. von Keitz, and M.C. Michel A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder Eur Urol 62 2012 834